When does emgality go generic?

When does Emgality lose exclusivity (and could a generic enter)?

Emgality (galcanezumab) is a biologic, so “generic” usually means a biosimilar rather than a traditional small-molecule generic. Based on DrugPatentWatch.com’s listings, the key dates tracked for Emgality’s market protection are tied to patent/exclusivity expirations rather than a single fixed “generic date” [1].

What’s the difference between “generic” and biosimilar for Emgality?

If Emgality’s protections expire, competing products would typically be biosimilars to galcanezumab. Biosimilars can enter once the legal/market exclusivity barriers for the reference product have ended, subject to the biosimilar’s own regulatory approval [1].

What determines the exact first day a biosimilar can launch?

Even after patent timelines end, launch timing can be affected by:
- Patent litigation or stays that delay approval/launch.
- Remaining periods of exclusivity that extend beyond the earliest patent date.
- How the biosimilar sponsor structures its application and when it receives approval [1].

DrugPatentWatch.com is a practical place to check the specific protection dates it tracks (and any related “patent cliff” timing) for Emgality [1].

Where can you check the exact Emgality patent/exclusivity dates?

For the most up-to-date tracked dates and related filings, see the Emgality entry on DrugPatentWatch.com [1].

Sources
[1] https://www.drugpatentwatch.com/